.beta.-amino acid derivatives

A pharmaceutical composition comprising a therapeutically-effective amount of a renin-inhibiting compound and a pharmaceutically-acceptable carrier or diluent, said renin-inhibiting compound selected from a family of compounds of the formula ##STR28## wherein R.sub.1 is selected from cycloalkyl and cycloalkylalkyl groups;

• wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and lower alkyl;
• wherein R.sub.3 is selected from hydrido, alkyl, benzyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl and alkylthioalkyl;
• wherein R.sub.5 is selected from cycloalkyl, phenyl, lower alkyl, cycloalkylalkyl and phenylalkyl;
• wherein R.sub.6 is selected from hydrido, hydroxy, alkoxy, amino, alkylamino, dialkylamino, lower alkyl and cycloalkyl;
• wherein R.sub.7 is selected from hydrido, alkyl, haloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkenyl and alkoxycarbonyl;
• wherein R.sub.6 and R.sub.7 may further be taken together to form a carbocyclic ring consisting of from three to about eight ring members;
• and wherein any of the foregoing R.sub.1 through R.sub.7 substituents having a substitutable position may be substituted with one or more groups selected from alkyl, alkoxy, halo, haloalkyl, alkenyl, alkynyl and cyano;
• or a pharmaceutically-acceptable salt thereof.

The composition of claim 9 wherein R.sub.1 is selected from cycloalkyl and cycloalkylalkyl groups, wherein said cycloalkyl group contains three to about ten carbon atoms and the acyclic alkyl portion of said cycloalkylalkyl group contains one to about ten carbon atoms;

• wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and lower alkyl;
• wherein R.sub.3 is selected from hydrido, alkyl, alkoxyalkyl and alkylthioalkyl;
• wherein R.sub.5 is selected from substituted or unsubstituted lower alkyl, cycloalkylalkyl and phenylalkyl;
• wherein R.sub.6 is selected from hydrido, hydroxy, alkoxy, amino, alkylamino and dialkylamino;
• wherein R.sub.7 is selected from hydrido, alkyl, haloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkenyl and alkoxycarbonyl;
• wherein R.sub.6 and R.sub.7 may further be taken together to form a carbocyclic ring consisting of from three to about six members;
• and wherein any of the foregoing R.sub.1 through R.sub.7 substituents having a substitutable position may be substituted with one or more groups selected from alkyl, alkoxy, halo, haloalkyl, alkenyl, alkynyl and cyano;
• or a pharmaceutically-acceptable salt thereof.

A therapeutic method for treating hypertension, said method comprising administering to a hypertensive patient a therapeutically-effective amount of a compound of the formula ##STR29## wherein R.sub.1 is selected from cycloalkyl and cycloalkylalkyl groups;

• wherein each of R.sub.2 and R.sub.4 is independently selected from hydrido and lower alkyl;
• wherein R.sub.3 is selected from hydrido, alkyl, benzyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl and alkylthioalkyl;
• wherein R.sub.5 is selected from cycloalkyl, phenyl, lower alkyl, cycloalkylalkyl and phenylalkyl;
• wherein R.sub.6 is selected from hydrido, hydroxy, alkoxy, amino, alkylamino, dialkylamino, lower alkyl and cycloalkyl;
• wherein R.sub.7 is selected from hydrido, alkyl, haloalkyl, cycloalkylalkyl, alkylcycloalkyl, alkylcycloalkenyl and alkoxycarbonyl;
• wherein R.sub.6 and R.sub.7 may further be taken together to form a carbocyclic ring consisting of from three to about eight ring members;
• and wherein any of the foregoing R.sub.1 through R.sub.7 substituents having a substitutable position may be substituted with one or more groups selected from alkyl, alkoxy, halo, haloalkyl, alkenyl, alkynyl and cyano;
• or a pharmaceutically-acceptable salt thereof.